BP Stock Soars as Oil Rally and Strategic Shift Boost Investor Confidence
8 November 2025
2 mins read

BP Stock Today (7 November 2025): ADR Hits 52‑Week High as Buybacks Continue; Oil Steadies and Brokers Weigh In

Summary: BP’s U.S. ADR set a fresh 52‑week high on Friday as the company pressed ahead with daily share repurchases and crude prices stabilized into the weekend. Broker commentary during 6–7 November stayed constructive, while London filings confirmed chunky buybacks across both days. 1


BP share price today (7 Nov 2025)

  • ADR close (NYSE: BP):$36.58, up ~2.1% on the day, marking a new 52‑week high and a fourth straight daily gain. MarketWatch also noted sub‑average volume, but enough momentum to eclipse the prior high set earlier this week. 1

What changed on 6–7 November

1) Daily buybacks confirmed in London
BP disclosed two consecutive “Transaction in Own Shares” notices:

  • 7 Nov: Repurchased 1,546,843 ordinary shares, with venue‑level volume‑weighted average prices around 458.6p; the day’s ranges topped out near 462.35p. Shares are intended for treasury. 2
  • 6 Nov: Repurchased 1,560,364 ordinary shares, VWAPs around 457.1p–457.5p across LSE and Cboe venues; intraday prices ranged roughly 454.05p–460.05p. Also headed to treasury. 3

These prints show the new $750m Q4‑ahead buyback announced earlier in the week is now fully in motion, with steady daily execution. 4

2) Oil price backdrop steadied
Crude trended firmer into Friday after mid‑week softness: Brent hovered ~$63–64/bbl on 6–7 Nov, with headlines citing oversupply concerns but a modest Friday rebound heading into the weekend. Saudi Arabia’s move to cut December OSPs and the latest OPEC+ supply signals also framed sentiment. For integrated majors like BP, even small stabilizations in crude can support short‑term equity moves. 5

3) London market color
On 6 Nov, the FTSE 100 extended its upswing helped by energy shares; BP gained ~1.6–1.8% intraday alongside firmer oil. 6

4) Fresh broker chatter
During the 6–7 Nov window, RBC reiterated “Sector Perform” on BP with a 500p price target, reflecting watchful optimism after the Q3 beat and buyback restart. (Aggregator summary.) 7


Context for the week: Q3 results and payout cadence

BP’s Q3 2025 print earlier this week came in better than feared, with underlying RC profit around $2.2bn, operating cash flow ~$7.8bn, and a new $750m buyback targeted for completion before Q4 results. The dividend remains 8.32c per share (quarterly). These updates set the tone for the later‑week share‑price strength and the daily buyback notices on 6–7 Nov. 8


Key takeaways for investors today

  • Momentum: The ADR closed at a 52‑week high on 7 Nov, extending a multi‑day rally. 1
  • Direct support from buybacks: Two straight days of 1.55–1.56m shares retired into treasury underscore active capital returns during the current program. 2
  • Macro still matters: Oil’s late‑week stabilization helped sentiment, but headlines continue to flag oversupply risk—keep an eye on OPEC+ signals and weekly U.S. inventory data. 9
  • Street stance:RBC 500p (Sector Perform) adds to the picture of tempered but constructive broker views following the Q3 update. 7

Timeline: 6–7 November (all times local market)

  • 6 Nov (London): BP files Transaction in Own Shares for 1,560,364 shares repurchased across LSE/Cboe; prices centered near 457p VWAP. 3
  • 6 Nov (Europe afternoon): Oil edges up after a mid‑week dip; sentiment improves into the close. FTSE 100 extends gains; BP advances with energy peers. 5
  • 7 Nov (London): Another BP buyback filing for 1,546,843 shares; ranges near 456–462p. 2
  • 7 Nov (U.S. close):BP ADR finishes at $36.58, a new 52‑week high; rally stretches to four sessions. 1

What to watch next

  • Daily RNS buyback prints: Expect continued disclosures while the $750m program runs toward completion ahead of the Q4 release window. 4
  • Oil tape: Direction of Brent after the latest OPEC+/OSP headlines will remain a near‑term swing factor for BP’s beta. 10

Disclosure & methodology: This article aggregates regulatory filings (RNS/Investegate), major wire services and market‑data sources dated 6–7 November 2025. Figures are based on official releases and widely used financial data providers; this is journalistic analysis, not investment advice. 2

Stock Market Today

XRP price today slips near $1.42 as thin weekend liquidity keeps traders on edge

XRP price today slips near $1.42 as thin weekend liquidity keeps traders on edge

7 February 2026
XRP fell about 5% Saturday to $1.42, extending a 22% weekly drop as thin liquidity and macro jitters drove sharp swings. Bitcoin rebounded above $70,000 after a brief plunge, while ether surged 12%. Ripple outlined plans for an “Institutional DeFi” roadmap, including a new lending protocol and permissioned DEX. The Federal Reserve held rates steady last week, with officials signaling caution on inflation.
Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

7 February 2026
Home Depot shares rose 0.7% to $385.15 Friday, trading between $379.10 and $386.37. Investors await a delayed U.S. jobs report Wednesday and CPI data Friday, both postponed by a brief government shutdown. Home Depot reports fourth-quarter earnings Feb. 24. The Dow closed above 50,000 for the first time.
JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

7 February 2026
JPMorgan shares rose 3.95% to $322.40 Friday, outpacing other major banks as U.S. stocks rallied and the Dow closed above 50,000 for the first time. The bank recently completed a $3 billion subordinated notes offering. Investors are watching for delayed U.S. jobs data and inflation figures next week, ahead of JPMorgan’s Feb. 23 company update.
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
Google Stock vs. Microsoft Stock in 2025 (through Nov. 7): Which Tech Titan Is Winning the AI Race?
Previous Story

Google Stock vs. Microsoft Stock in 2025 (through Nov. 7): Which Tech Titan Is Winning the AI Race?

Tech Stocks Storm the Market: QQQ Rockets on Trade Truce while TQQQ Investors Cash In (Oct 14, 2025)
Next Story

QQQ vs. QQQM vs. VGT on Nov. 7, 2025: After Tech’s Worst Week Since April, Which ETF Still Looks Best?

Go toTop